Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Chuikyo Supports Price Raise Rules for Cost-Effective Products
November 8, 2018
- MHLW Pitches “Tiered Model” for CEA Price Tweak, but Faces Chuikyo Opposition
November 8, 2018
- FY2019 Tax Reform Debate Going into Full Swing; Will Pharma Industry Win Expansion in R&D Credit?
November 7, 2018
- Freeze-Dried BCG Vaccine Shipment Suspended due to Arsenic in Diluent; MHLW Panel Calls for Switch to New Product
November 7, 2018
- MHLW Sets Carcinogen Limits in ARBs after Valsartan Impurity Issue
November 6, 2018
- AMED Study Group to Draft Guidelines to Promote Expanded Indications for Neuropathic Pain Drugs
November 6, 2018
- Advocacy Groups Submit Petition for Rubella Prevention, Control Measures to LDP Committee
November 6, 2018
- Public-Private Policy Dialogue Set for November 12
November 5, 2018
- LDP’s Eto Study Group Opposes 2-Stage Revision in 2019
November 2, 2018
- MHLW Asks 5 Prefectures to Cooperate in Distribution of MR Vaccines
November 2, 2018
- MHLW Panel to Discuss Changing Current Transitional Period for Pneumococcal Vaccinations in Elderly
November 2, 2018
- Chuikyo Leaning towards Drug Price Revision in October 2019 in Conjunction with Tax Hike
November 1, 2018
- Infection Specialist Proposes to Set Up Vaccination Council within Cabinet Office
October 31, 2018
- Daiichi Sankyo to Use MID-NET Database for Pralia PMS; Second Case from Private Sector
October 31, 2018
- MHLW Council to Discuss Otsuka’s Nalmefene for Treatment of Alcohol Dependency on Nov. 9
October 29, 2018
- ViiV’s HIV Med Juluca Up for MHLW Panel Review on Nov. 8
October 26, 2018
- MHLW to Map Out Additional Step against Rubella Outbreak by Year-End
October 25, 2018
- MHLW Warns against Advertising Claims Suggesting that OTC Cinnamon Bark Products Can Cure Diabetes
October 25, 2018
- AMED Selects 10 More Projects for CiCLE Grant Program, 4 for New Program to Support Startups
October 24, 2018
- MHLW Orders Label Revisions for Lamotrigine to Include Hemophagocytic Syndrome in ADR List
October 24, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…